Literature DB >> 29795360

Plasma miR-451 with echocardiography serves as a diagnostic reference for pulmonary hypertension.

Xiao-Wei Song1, Lu-Lu Zou1, Ling Cui1, Song-Hua Li1, Yong-Wen Qin1, Xian-Xian Zhao1, Qing Jing2,3.   

Abstract

Due to the lack of typical clinical symptoms, the average delay time for diagnosis of pulmonary hypertension (PH) is longer than 2 years. It is urgent to find biomarkers for PH diagnosis. In this study we investigated whether plasma microRNAs (miRNAs) can be used as biomarkers for PH diagnosis. We used microarray to identify dynamic miRNAs between PH and non-PH patients. The candidate miRNAs were verified using qRT-PCR in a mouse model of PH, which was induced by monocrotaline (MCT) injection. We observed that miR-21, miR-126, miR-145, miR-191 and miR-150 had no differences between control mice and MCT-treated mice; but plasma miR-451 was significantly decreased in the 2wk-MCT group, with no further decrease in the 4wk-MCT group. Plasma miR-451 was also markedly decreased in PH patients, whereas miR-21, miR-126, miR-150 and miR-320 did not show differences between 53 PH patients and 54 non-PH patients. Receiver operating characteristic curves (ROCs) were constructed from the patient data to assess the clinical diagnostic values of circulating miR-451 and Doppler echocardiography (D-ECHO). The areas under the curve (AUCs) of ROCs for miR-451 and D-ECHO were 0.710 and 0.766, respectively. Combination of miR-451 and D-ECHO with AUC of 0.825 was superior to the use of either miR-451 or D-ECHO alone for PH diagnosis. In conclusion, plasma miR-451 has a moderate diagnostic value in PH comparable to that of D-ECHO, and the combination of miR-451 with D-ECHO has better diagnostic value than either method alone, which may have implications for PH diagnosis.

Entities:  

Keywords:  D-ECHO; biomarker; miR-451; miRNAs; pulmonary hypertension

Mesh:

Substances:

Year:  2018        PMID: 29795360      PMCID: PMC6289348          DOI: 10.1038/aps.2018.39

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  41 in total

1.  [Diagnosis and treatment of pulmonary hypertension: European guidelines 2009].

Authors:  M M Hoeper; H A Ghofrani; M Gorenflo; E Grünig; D Schranz; S Rosenkranz
Journal:  Pneumologie       Date:  2010-05-18

2.  Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension.

Authors:  Anna Fijalkowska; Marcin Kurzyna; Adam Torbicki; Grzegorz Szewczyk; Michal Florczyk; Piotr Pruszczyk; Monika Szturmowicz
Journal:  Chest       Date:  2006-05       Impact factor: 9.410

3.  Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy.

Authors:  Qing Li; Xiao-Wei Song; Jun Zou; Guo-Kun Wang; Elena Kremneva; Xiang-Qi Li; Ni Zhu; Tao Sun; Pekka Lappalainen; Wen-Jun Yuan; Yong-Wen Qin; Qing Jing
Journal:  J Cell Sci       Date:  2010-06-22       Impact factor: 5.285

4.  Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era.

Authors:  Marc Humbert; Olivier Sitbon; Ari Chaouat; Michèle Bertocchi; Gilbert Habib; Virginie Gressin; Azzedine Yaïci; Emmanuel Weitzenblum; Jean-François Cordier; François Chabot; Claire Dromer; Christophe Pison; Martine Reynaud-Gaubert; Alain Haloun; Marcel Laurent; Eric Hachulla; Vincent Cottin; Bruno Degano; Xavier Jaïs; David Montani; Rogério Souza; Gérald Simonneau
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

5.  Pulmonary hypertension produced in rats by ingestion of Crotalaria spectabilis seeds.

Authors:  J M Kay; P Harris; D Heath
Journal:  Thorax       Date:  1967-03       Impact factor: 9.139

6.  A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples.

Authors:  Paola Caruso; Yvonne Dempsie; Hannah C Stevens; Robert A McDonald; Lu Long; Ruifang Lu; Kevin White; Kirsty M Mair; John D McClure; Mark Southwood; Paul Upton; Mei Xin; Eva van Rooij; Eric N Olson; Nicholas W Morrell; Margaret R MacLean; Andrew H Baker
Journal:  Circ Res       Date:  2012-06-19       Impact factor: 17.367

7.  Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages.

Authors:  Yukihiro Akao; Akio Iio; Tomohiro Itoh; Shunsuke Noguchi; Yuko Itoh; Yoshinori Ohtsuki; Tomoki Naoe
Journal:  Mol Ther       Date:  2010-11-23       Impact factor: 11.454

8.  Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension.

Authors:  B Sztrymf; R Souza; L Bertoletti; X Jaïs; O Sitbon; L C Price; G Simonneau; M Humbert
Journal:  Eur Respir J       Date:  2009-11-06       Impact factor: 16.671

9.  MicroRNA-424(322) as a new marker of disease progression in pulmonary arterial hypertension and its role in right ventricular hypertrophy by targeting SMURF1.

Authors:  Rui Baptista; Carla Marques; Steve Catarino; Francisco J Enguita; Marina C Costa; Paulo Matafome; Mónica Zuzarte; Graça Castro; Abílio Reis; Pedro Monteiro; Mariano Pêgo; Paulo Pereira; Henrique Girão
Journal:  Cardiovasc Res       Date:  2018-01-01       Impact factor: 10.787

10.  Role for miR-204 in human pulmonary arterial hypertension.

Authors:  Audrey Courboulin; Roxane Paulin; Nellie J Giguère; Nehmé Saksouk; Tanya Perreault; Jolyane Meloche; Eric R Paquet; Sabrina Biardel; Steeve Provencher; Jacques Côté; Martin J Simard; Sébastien Bonnet
Journal:  J Exp Med       Date:  2011-02-14       Impact factor: 14.307

View more
  7 in total

1.  Circulating biomarkers for cardiovascular diseases: the beats never stop.

Authors:  Lei Xi; George Kouvelos; Nazareno Paolocci
Journal:  Acta Pharmacol Sin       Date:  2018-07       Impact factor: 6.150

2.  Increased Methyl-CpG-Binding Domain Protein 2 Promotes Cigarette Smoke-Induced Pulmonary Hypertension.

Authors:  Jixing Wu; Qian Huang; Qinghai Li; Yiya Gu; Yuan Zhan; Ting Wang; Jinkun Chen; Zhilin Zeng; Yongman Lv; Jianping Zhao; Jie Xia; Jungang Xie
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

3.  Serum miR-204 and miR-451 Expression and Diagnostic Value in Patients with Pulmonary Artery Hypertension Triggered by Congenital Heart Disease.

Authors:  Dejiang Ji; Yan Qiao; Xiaoping Guan; Tao Zhang
Journal:  Comput Math Methods Med       Date:  2022-06-13       Impact factor: 2.809

Review 4.  Noncoding RNAs in Hypertension.

Authors:  Amela Jusic; Yvan Devaux
Journal:  Hypertension       Date:  2019-07-29       Impact factor: 10.190

5.  Absence of the MFG-E8 gene prevents hypoxia-induced pulmonary hypertension in mice.

Authors:  Jun Wang; Jixing Wu; Xianying Zhu; Jinkun Chen; Jianping Zhao; Yongjian Xu; Jungang Xie
Journal:  J Cell Physiol       Date:  2020-06-27       Impact factor: 6.384

Review 6.  Non-Coding RNAs as Blood-Based Biomarkers in Cardiovascular Disease.

Authors:  Raquel Figuinha Videira; Paula A da Costa Martins; Inês Falcão-Pires
Journal:  Int J Mol Sci       Date:  2020-12-05       Impact factor: 5.923

7.  Deletion of the miR-144/451 cluster aggravates lethal sepsis-induced lung epithelial oxidative stress and apoptosis.

Authors:  Fan Wu; Xiaoling Yuan; Weili Liu; Lijun Meng; Xiuru Li; Xiang Gao; Shuting Zhou; Lei Fang; Duonan Yu
Journal:  Ann Transl Med       Date:  2022-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.